Last SFr.2.35 CHF
Change Today 0.00 / 0.00%
Volume 0.0
ADXN On Other Exchanges
Symbol
Exchange
ADXN is not on other exchanges.
As of 11:43 AM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

addex pharmaceuticals ltd (ADXN) Snapshot

Open
SFr.2.37
Previous Close
SFr.2.35
Day High
SFr.2.37
Day Low
SFr.2.30
52 Week High
07/4/14 - SFr.5.24
52 Week Low
05/5/14 - SFr.1.28
Market Cap
23.9M
Average Volume 10 Days
26.8K
EPS TTM
SFr.-1.60
Shares Outstanding
10.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADDEX PHARMACEUTICALS LTD (ADXN)

Related News

No related news articles were found.

addex pharmaceuticals ltd (ADXN) Related Businessweek News

No Related Businessweek News Found

addex pharmaceuticals ltd (ADXN) Details

Addex Therapeutics Ltd., together with its subsidiaries, is engaged in the discovery, development, and commercialization of small-molecule pharmaceutical products for the treatment of human health. The company’s lead products include dipraglurant ADX48621, a metabotropic glutamate receptor (mGluR) 5 negative allosteric modulator that is in Phase IIa clinical trial for the treatment of Parkinson’s disease levodopa-induced dyskinesia; and ADX71149, an mGluR2 positive allosteric modulator (PAM), which is under Phase IIa clinical trial to treat schizophrenia and anxiety. It also develops various preclinical programs comprising GABA-BR PAM for overactive bladder and other disorders; mGluR4 PAM for the treatment of Parkinson’s, multiple sclerosis, and other diseases; GLP1R PAM for type 2 diabetes; and mGluR2 NAM for treating Alzheimer's disease and depression. In addition, the company has discovery programs to identify allosteric modulators, including TrkB PAM for neurodegenerative diseases; and TNFR1 NAM for inflammatory diseases. The company’s product under development also includes ADX71441 for the treatment of alcohol addiction, Charcot-Marie-Tooth disease, and other indications. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGlu2PAM compounds for the treatment of human health. The company was formerly known as Addex Pharmaceuticals Ltd. and changed its name to Addex Therapeutics Ltd. in March 2012. Addex Therapeutics Ltd. was founded in 2002 and is headquartered in Geneva, Switzerland.

5 Employees
Last Reported Date: 05/31/14
Founded in 2002

addex pharmaceuticals ltd (ADXN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.358.9K
Compensation as of Fiscal Year 2013.

addex pharmaceuticals ltd (ADXN) Key Developments

Addex Amends mGlu2PAM Collaboration Agreement and Receives USD 757,000

Addex Therapeutics announced that it has received USD 757,000 from Janssen Pharmaceuticals Inc., following the amendment of their mGlu2PAM research collaboration and license agreement. Under the agreement signed between Addex and Janssen in 2004, Addex was required to finance 50% of the cost of all jointly owned patents. Under this amendment, certain jointly owned patents have been assigned to Janssen and all past patent costs paid by Addex have been reimbursed by Janssen to Addex. Going forward, Addex contribution to patent costs has been significantly reduced. This amendment has no impact on Addex right to receive royalties and milestones under the agreement.

Addex Therapeutics Enters in to Collaboration with Charcot-Marie-Tooth Association to Evaluate the Pharmacology of ADX71441

Addex Therapeutics announced entering a collaboration with the Charcot-Marie-Tooth Association (CMTA) to evaluate the pharmacology of ADX71441, a GABA-B receptor positive allosteric modulator (PAM) in a battery of preclinical models of Charcot-Marie-Tooth 1A disorder (CMT1A), a rare hereditary motor and sensory demyelinating peripheral neuropathy. The CMTA consortium will evaluate the efficacy of ADX71441 as a pharmacological agent in preclinical neurological and behavioral models of CMT1A and will assess the potential of ADX71441 to impede the development of motor and sensory control defects associated with normal disease progression. Both clinical and pre-clinical data suggest that activation of GABA-B receptors offers a unique therapeutic opportunity to address the needs of patients with CMT1A. Addex has previously announced a positive proof of concept in a validated pre-clinical model of Charcot-Marie-Tooth 1A (CMT1A) with ADX71441, confirming previous observations obtained using a GABA-B receptor agonist and the GABAB1-/- knock-out mice. This model identified the importance of GABA-B receptors in inhibiting proliferation and reduction of synthesis of specific myelin proteins, in particular, in lowering the toxic PMP22 overexpression, which in turn, may delay disease progression.

Addex Therapeutics Ltd. Announces Earning Results for the First Half of 2014

Addex Therapeutics Ltd. announced earning results for the first half of 2014. For the first half, the company reported total operating loss was CHF 967,000 compared with CHF 13,933,000 a year ago. Net loss for the period was CHF 970,000 compared with CHF 13,937,000 a year ago. Basic and diluted net loss per share were CHF 0.10 compared with CHF 1.61 a year ago. Net cash used CHF 816,000 compared with CHF 10,778,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADXN:SW SFr.2.35 CHF 0.00

ADXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADXN.
View Industry Companies
 

Industry Analysis

ADXN

Industry Average

Valuation ADXN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 10.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADDEX PHARMACEUTICALS LTD, please visit www.addextherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.